These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. Parravano M; Menchini F; Virgili G Cochrane Database Syst Rev; 2009 Oct; (4):CD007419. PubMed ID: 19821414 [TBL] [Abstract][Full Text] [Related]
24. Lipids, hyperreflective crystalline deposits and diabetic retinopathy: potential systemic and retinal-specific effect of lipid-lowering therapies. Jenkins AJ; Grant MB; Busik JV Diabetologia; 2022 Apr; 65(4):587-603. PubMed ID: 35149880 [TBL] [Abstract][Full Text] [Related]
25. Head-to-head comparison of fibrates versus statins for elevation of circulating adiponectin concentrations: a systematic review and meta-analysis. Sahebkar A Metabolism; 2013 Dec; 62(12):1876-85. PubMed ID: 24095632 [TBL] [Abstract][Full Text] [Related]
30. Neuroprotection for treatment of glaucoma in adults. Sena DF; Lindsley K Cochrane Database Syst Rev; 2017 Jan; 1(1):CD006539. PubMed ID: 28122126 [TBL] [Abstract][Full Text] [Related]
31. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Perkovic V; Hegbrant J; Strippoli GF Cochrane Database Syst Rev; 2014 May; (5):CD007784. PubMed ID: 24880031 [TBL] [Abstract][Full Text] [Related]
32. Potential utility of statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in diabetic retinopathy. Yamagishi S; Nakamura K; Matsui T; Sato T; Takeuchi M Med Hypotheses; 2006; 66(5):1019-21. PubMed ID: 16188392 [TBL] [Abstract][Full Text] [Related]
33. Statin-associated incident diabetes: a literature review. Park ZH; Juska A; Dyakov D; Patel RV Consult Pharm; 2014; 29(5):317-34. PubMed ID: 24849689 [TBL] [Abstract][Full Text] [Related]
34. Use of fibrates in clinical practice: Queensland Lipid Group consensus recommendations. Hamilton-Craig I; Kostner KM; Woodhouse S; Colquhoun D Int J Evid Based Healthc; 2012 Sep; 10(3):181-90. PubMed ID: 22925614 [TBL] [Abstract][Full Text] [Related]
36. Lipid-lowering agents for nephrotic syndrome. Kong X; Yuan H; Fan J; Li Z; Wu T; Jiang L Cochrane Database Syst Rev; 2013 Dec; (12):CD005425. PubMed ID: 24327265 [TBL] [Abstract][Full Text] [Related]
37. Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy. Smith JM; Steel DH Cochrane Database Syst Rev; 2011 May; (5):CD008214. PubMed ID: 21563165 [TBL] [Abstract][Full Text] [Related]
38. Global prevalence of diabetic retinopathy: protocol for a systematic review and meta-analysis. Cheloni R; Gandolfi SA; Signorelli C; Odone A BMJ Open; 2019 Mar; 9(3):e022188. PubMed ID: 30833309 [TBL] [Abstract][Full Text] [Related]
39. Tailored Communication Within Mobile Apps for Diabetes Self-Management: A Systematic Review. Holmen H; Wahl AK; Cvancarova Småstuen M; Ribu L J Med Internet Res; 2017 Jun; 19(6):e227. PubMed ID: 28645890 [TBL] [Abstract][Full Text] [Related]